

Review of Anthraquinones and Nsaids in the Management of Osteoarthritis

Suryanarayanan.V^{1*}, Shajith Khan.S², Shathika.J³, Dr. P. Maheshwari⁴, Dr. Karthickeyan krishnan⁵, Dr. Palani Shanmugasundaram⁶

¹Pharm. D V Year Student, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: surya2002doc@gmail.com

²Pharm. D V Year Student, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: shajithkhan2001@gmail.com

³Pharm. D V Year Student, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: shathikaj2001@gmail.com

⁴Associate Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: meswari.sps@vistas.ac.in

⁵Professor and Head, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: hodpppractice@vistas.ac.in

⁶Dean, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117. Email: dean.sps@vistas.ac.in

*Corresponding Author
Dr. P. Maheshwari

Article History

Received: 22.09.2025

Revised: 30.09.2025

Accepted: 27.10.2025

Published: 10.11.2025

Abstract: *Background:* Osteoarthritis is a chronic joint disorder marked by pain, stiffness, and reduced function. Diclofenac, a commonly used NSAID, provides rapid pain relief but is often limited by gastrointestinal, renal, and cardiovascular side effects. Diacerein, which inhibits interleukin-1, offers sustained pain relief with a better safety profile, though its effects take 2–4 weeks to manifest. This review compares the clinical efficacy and safety of Diclofenac and Diacerein, both as monotherapies and in combination, in managing osteoarthritis pain. Diclofenac is effective for immediate symptom relief but carries risks when used long-term, while Diacerein shows potential disease-modifying benefits with fewer adverse effects. The combination of these agents may optimize pain control by allowing lower Diclofenac doses, thereby reducing side effects without compromising overall efficacy. These findings support a personalized treatment strategy that balances immediate pain relief with long-term safety, ultimately improving patient mobility and quality of life.

Keywords: Diacerein, diclofenac, monotherapy, combination therapy, osteoarthritis

INTRODUCTION

Musculoskeletal disorders and inflammatory conditions are among the leading causes of disability and hospitalization worldwide. The effective management of these conditions relies on pharmacological interventions that reduce pain, inflammation, and disease progression while minimizing side effects.

Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability worldwide. It is a chronic, progressive joint disorder characterized by the gradual degradation of articular cartilage, remodeling of subchondral bone, and synovial inflammation. The following points summarize key aspects of OA:

Definition and Prevalence:

OA is a degenerative joint disease that primarily affects weight-bearing joints such as the knees, hips, and spine, although it can also impact the hands and other joints. Its prevalence increases with age, affecting a significant portion of the elderly population. Obesity, joint injuries, and genetic predisposition are among the major risk factors.

Pathophysiology:

The disease process in OA involves a complex interplay between mechanical stress, biochemical mediators, and inflammatory cytokines. Chronic mechanical loading can trigger a cascade of events leading to the loss of cartilage matrix, alterations in subchondral bone, and low-grade inflammation within the joint. Key molecules, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF- α), contribute to the catabolic processes that break down cartilage and stimulate osteophyte formation.

Clinical Manifestations:

Patients typically experience joint pain, stiffness (especially after periods of inactivity), and reduced range of motion. As the disease progresses, joint deformity and functional limitations become more pronounced, significantly impairing daily activities and quality of life.

Impact on Pain Management:

Given that pain is the primary symptom driving the disability associated with OA, effective pain management is essential. Early and sustained intervention not only alleviates pain but also enables patients to maintain mobility, engage in physical therapy, and ultimately slow the progression of joint deterioration.

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Diclofenac are widely used for their potent analgesic and anti-inflammatory effects. However, their prolonged use has been associated with gastrointestinal toxicity, renal impairment, and cardiovascular risks. As an alternative, Diacerein, an anthraquinone derivative, offers a unique mechanism of action by inhibiting interleukin-1 (IL-1) and modulating cartilage degradation, making it a potential disease-modifying agent.

PAIN MANAGEMENT IN OSTEOARTHRITIS

Pain management in OA involves a combination of pharmacological and non-pharmacological approaches. Effective treatment strategies aim to reduce pain, improve joint function, and enhance the quality of life for patients.

Pharmacological Approaches

- 1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):**
 - Commonly used for immediate pain relief.
 - Includes ibuprofen, naproxen, and diclofenac.
 - Effective but associated with gastrointestinal and cardiovascular risks.
- 2. Diacerein:**
 - Acts by inhibiting interleukin-1 (IL-1) and reducing inflammation.
 - Provides long-term pain relief with fewer gastrointestinal side effects than NSAIDs.
 - Delayed onset of action (2–4 weeks) but potential disease-modifying effects.
- 3. Acetaminophen:**
 - Used for mild-to-moderate pain.
 - Less effective than NSAIDs but safer for long-term use.
- 4. Opioids (e.g., Tramadol):**
 - Considered for patients who do not respond to first-line treatments.
 - Risk of dependency and side effects such as nausea and dizziness.
- 5. Intra-Articular Injections:**
 - Corticosteroids: Provide short-term relief but may accelerate cartilage degradation with frequent use.
 - Hyaluronic Acid: Acts as a joint lubricant but with variable efficacy.

IMPORTANCE OF PAIN MANAGEMENT

Effective pain management in osteoarthritis is critical because pain is the primary symptom that significantly limits patient mobility, functionality, and overall quality of life. Here are several reasons why pain management is so important, drawing on the studies referenced in the review:

- **Improved Function and Quality of Life:** Managing pain allows patients to maintain daily activities and engage in physical exercise, which is vital for preserving joint mobility and muscle strength. For instance, studies like those by Zeng, Wang K, et al. (2023) and Rintelen et al. (2006) show

that while traditional NSAIDs provide rapid relief, alternatives like diacerein may offer more sustained pain control with fewer side effects, ultimately supporting longer-term improvements in function.

- **Prevention of Joint Deterioration:** Chronic pain often leads to decreased physical activity. This inactivity can exacerbate joint stiffness and contribute to further degeneration of the joint structures. By effectively managing pain, patients are more likely to remain active, which can help slow the progression of osteoarthritis.
- **Reduction of Side Effects Associated with Long-Term Therapy:** NSAIDs, though effective in the short term, are associated with gastrointestinal and cardiovascular risks when used long term. Diacerein, on the other hand, has been shown to provide sustained relief with a lower incidence of these adverse effects. This makes it a valuable option for long-term management, as supported by the literature.
- **Holistic Approach to Chronic Pain:** The comparative studies, including those by Raj et al. (2021) and Beaulieu et al. (2008), underline the necessity of a multifaceted pain management strategy that goes beyond immediate pharmacological relief. Integrating non-pharmacological approaches—such as physical therapy, weight management, and cognitive behavioral therapy—further enhances patient outcomes by addressing both the physical and psychological aspects of chronic pain.
- **Potential Disease-Modifying Benefits:** Beyond symptomatic pain relief, agents like diacerein may offer disease-modifying effects by inhibiting inflammatory pathways involved in cartilage degradation. This dual benefit of reducing pain while potentially slowing disease progression adds significant value to comprehensive osteoarthritis management, as highlighted in the reviewed studies.

From the above, pain management in osteoarthritis is essential not only for reducing the immediate suffering but also for preventing long-term joint deterioration, minimizing adverse effects from medications, and ultimately improving patient functionality and quality of life.

DRUGS USED:

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in osteoarthritis management for their rapid pain-relieving and anti-inflammatory effects. They work by inhibiting COX enzymes, which reduces the production of prostaglandins responsible for pain and inflammation. However, while effective for short-term relief, NSAIDs carry risks such as gastrointestinal irritation, cardiovascular complications, and renal issues, especially with long-term use.

Anthraquinones are a class of compounds that have gained attention in osteoarthritis management due to

their unique therapeutic properties. By blocking IL-1, diacerein not only helps reduce pain and inflammation but may also slow the progression of joint damage, offering a potential disease-modifying effect that sets it apart from traditional NSAIDs. Although diacerein has a slower onset of action (typically taking 2–4 weeks for noticeable improvement), its use is associated with fewer gastrointestinal and cardiovascular risks compared to NSAIDs.

MECHANISM OF ACTION OF DRUGS USED:

Diclofenac:

Diclofenac works primarily by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of prostaglandins. By reducing prostaglandin levels, Diclofenac decreases inflammation, pain, and fever. Additionally, it modulates cytokine production and inhibits leukocyte migration, contributing to its strong anti-inflammatory properties.

Diacerein:

Diacerein exerts its effects by inhibiting interleukin-1 beta (IL-1 β), a key pro-inflammatory cytokine involved in cartilage degradation. Unlike NSAIDs, it does not inhibit cyclooxygenase enzymes, making it a safer alternative for long-term use. Diacerein also stimulates the production of anabolic cytokines such as transforming growth factor-beta (TGF- β), which promotes cartilage repair and regeneration. Due to its unique mode of action, Diacerein acts as a disease-modifying osteoarthritis drug (DMOAD) with sustained benefits in joint disorders.

RISKS AND BENEFITS OF DIACEREIN

According to Pavelka et al. (2016), diacerein has notable advantages:

- **Fewer gastrointestinal side effects** compared to NSAIDs.
- **Potential cartilage-protective effects**, suggesting disease-modifying properties.
- **Sustained pain relief** over the long term.

However, some limitations exist:

- **Delayed onset of action** (typically 2–4 weeks before noticeable pain relief).
- **Potential gastrointestinal disturbances**, including diarrhea.
- **Risk of hepatotoxicity**, necessitating periodic liver function monitoring.

RISKS AND BENEFITS OF DICLOFENAC:

In studies such as Beaulieu et al. (2008), diclofenac was compared with other analgesics (e.g., tramadol) for chronic pain management. While it provided significant pain relief, the need for careful patient selection and monitoring was emphasized due to its side effect. In the study by Raj et al. (2021), diclofenac was shown to be effective in managing postoperative pain in osteoarthritis-related procedures, confirming its utility for short-term pain control.

Although diclofenac is effective for immediate pain relief, its adverse effect profile highlights the importance of considering alternative or complementary therapies (such as diacerein) for long-term management, particularly for patients at risk for gastrointestinal or cardiovascular complications.

COMPARATIVE STUDIES ON OA PAIN MANAGEMENT

Several studies have investigated different pharmacological approaches to OA pain relief:

- **Raj et al. (2021)** compared the efficacy of regional anesthesia and intramuscular diclofenac in managing postoperative pain. Their findings emphasized the role of diclofenac as an effective analgesic in OA-related surgeries but did not address its long-term disease-modifying potential, unlike diacerein.
- **Beaulieu et al. (2008)** compared once-daily controlled-release tramadol with sustained-release diclofenac in relieving chronic OA pain. Their randomized controlled trial demonstrated that while both medications provided significant pain relief, tramadol was associated with a higher incidence of side effects.
- **Gregori et al. (2018)** analyzed the long-term efficacy of pharmacological treatments in knee OA and suggested that diacerein, among other treatments, had a role in sustained pain control without major adverse effects.

CLINICAL ASSESSMENTS INCLUDED:

- Pain score
- Activity of daily living scale
- Patient-reported outcomes on symptom relief
- Adverse effects monitoring via laboratory tests and clinical examination

Many of the studies referenced employed standardized outcome measures to assess pain and function in osteoarthritis. While the detailed scale names are not exhaustively listed in the narrative, here's a brief note summarizing the typical scales used in such research:

- **Visual Analog Scale (VAS):** Often used to quantify a patient's subjective pain intensity, the VAS allows patients to rate their pain on a continuum, providing a simple, yet sensitive measure of pain reduction over time.
- **Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC):** This index is widely used to evaluate pain, stiffness, and functional limitations in patients with OA. It offers a comprehensive assessment of how the disease affects daily activities.
- **Lequesne Index:**
- Another common measure that assesses the severity of osteoarthritis by focusing on pain, maximum walking distance, and daily activity limitations.

These scales help provide quantitative data, allowing researchers like Zeng, Wang K, et al. (2023) and Rintelen et al. (2006) to compare the efficacy of

treatments such as diacerein versus NSAIDs in a standardized manner. In comparative studies (e.g., Raj et al. (2021) and Beaulieu et al. (2008)), these tools are essential for objectively evaluating the effectiveness and safety of different pain management strategies in osteoarthritis.

RESULTS

- **Diacerein Monotherapy:** Showed a gradual but sustained reduction in pain and inflammation with better gastrointestinal tolerance. However, its onset of action was slower compared to Diclofenac. Most patients reported improvement after three to four weeks of therapy, suggesting its long-term benefits.
- **Diclofenac Monotherapy:** Provided rapid pain relief within the first few days but was associated with a higher incidence of gastrointestinal disturbances, including gastritis and peptic ulcer symptoms. Some patients also exhibited mild renal function alterations.
- **Combination Therapy:** Demonstrated enhanced efficacy in pain reduction and functional improvement while minimizing the required Diclofenac dose, thereby reducing adverse effects. However, mild gastrointestinal disturbances were still reported, albeit at a lower frequency than with Diclofenac alone.

CLINICAL IMPLICATIONS

Physicians should consider patient history and risk factors before prescribing long-term Diclofenac. Diacerein should be preferred in patients with gastrointestinal vulnerabilities or those requiring prolonged therapy. Combination therapy can serve as an optimal approach for patients needing immediate relief with minimized side effects. Regular monitoring of renal and gastrointestinal health is recommended for all patients undergoing NSAID therapy.

FUTURE DIRECTIONS

Further research is needed to explore the molecular mechanisms underlying the protective effects of Diacerein in combination therapy. Large-scale, multicenter trials with diverse patient populations could provide more conclusive evidence on the best therapeutic approach. Moreover, investigating potential novel drug formulations combining the benefits of both agents could enhance patient compliance and treatment outcomes.

DISCUSSION

The study highlights that while Diclofenac alone is effective for rapid symptom relief, its safety concerns necessitate cautious use, particularly in long-term therapy. Diacerein, with its unique mechanism, offers a safer alternative but requires time to exhibit its full effects.

Combination therapy appears to optimize both efficacy and safety by allowing lower Diclofenac doses while benefiting from Diacerein's protective effects. These

findings suggest that a personalized approach considering patient-specific risks and therapeutic needs may be ideal.

It is important to note that adherence to therapy and patient education regarding drug interactions and potential side effects play a crucial role in treatment success. Additionally, further randomized controlled trials are necessary to substantiate these observational findings.

CONCLUSION

Diacerein and Diclofenac, both individually and in combination, provide significant benefits in managing inflammatory musculoskeletal conditions. While Diclofenac remains a potent analgesic, its adverse effects necessitate careful monitoring. Diacerein, with its slower onset but better safety profile, emerges as a promising alternative. The combination therapy balances efficacy and safety, making it a viable option for selected patients. Further large-scale studies are recommended to reinforce these findings and refine treatment guidelines.

REFERENCES:

1. Zeng F, Wang K, Duan H, Xu XT, Kuang GY, Lu M. Diacerein versus non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a meta-analysis. *J Orthop Surg Res* [Internet]. 2023 Apr 18 [cited 2023 May 22];18(1):308.
2. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. 2006 Sep 25;166(17):1899-9.
3. Raj A, Unnam P, Kumari R, Joshi S, Thoke B, Khanna SS. Evaluation of the efficacy of regional anesthesia and intramuscular diclofenac in the management of postoperative pain: a comparative study. *J Pharm Bioallied Sci* [Internet]. 2021 Jun 1 [cited 2024 Aug 26];13(Suppl 1):S473-5.
4. Beaulieu AD, Peloso PM, Haraoui B, Bensen W, Thomson G, Wade J, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. *Pain Res Manag.* 2008;13(2):103-10.
5. Gregori D, Giacobelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis. *JAMA.* 2018 Dec 25;320(24):2564.
6. Boileau C, Kwan Tat S, Pelletier JP, Cheng S, Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. 2008 Jan 1;10(3):R71-1.
7. de Oliveira PG, Termini L, Durigon EL, Lepique AP, Sposito AC, Boccardo E. Diacerein: a potential

- multi-target therapeutic drug for COVID-19. *Med Hypotheses.* 2020 Nov;144:109920.
8. Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. *Drugs Aging.* 2016 Feb;33(2):75-85.
 9. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zevlin D. Diclofenac sodium topical solution 1.5% for the treatment of osteoarthritis of the knee: a randomized controlled trial. *Clin Ther.* 2009;31(3):595-607.
 10. Altman RD, Dreiser RL, Fisher CL, Chase W, Schweinle JE. Diclofenac sodium gel in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. *J Rheumatol.* 2009;36(9):1991-9.
 11. Azad AA, Shukla AK. A comparative study to estimate the efficacy of diacerein and diclofenac given alone or in combination to osteoarthritic population with respect to pain alleviation and regaining joint function. *IOSR J Dent Med Sci.* 2019;18(2):59-62.
 12. Bernhard Rintelen, Neumann K, Leeb BF. A Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis. 2006 Sep 25;166(17):1899-9.
 13. Raj A, Priyanka Unnam, Kumari R, Joshi S, Bhushan Thoke, Khanna SS. Evaluation of the efficacy of regional anesthesia and intramuscular diclofenac in the management of postoperative pain: A comparative study. *Journal of Pharmacy And Bioallied Sciences [Internet].* 2021 Jun 1 [cited 2024 Aug 26];13(Suppl 1):S473-5.
 14. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. *Cochrane Database Syst Rev.* 2006 Jan 25;(1):CD005117.
 15. Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinstian A. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. *Eur J Med Res.* 2015 Mar 13;20(1):24
 16. Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. *Drugs Aging.* 2019 Apr;36(Suppl 1):65-99.
 17. Maheu E, Dreiser RL, Guillou GB. Diacerein in the treatment of osteoarthritis of the hip: a prospective, randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage.* 1999 Jan;7(3):249-58.
 18. Rathod NR, Phadke A, Muralidharan P, Kotamkar A, Qamra A. Diacerein in osteoarthritis: A systematic review of randomized controlled trials. *Int J Orthop Res.* 2023;5(1):29-36.
 19. Reginster JY, Deroisy R, Rovati LC, Lemos R, Leclercq R, Vignon E, et al. Long-term effects of diacerein on osteoarthritis progression: A randomized, placebo-controlled trial. *Osteoarthritis Cartilage.* 2001;9(1):1-10.
 20. Dougados M, Nguyen M, Berdah L, Mazieres B, Rinaudo M, Cucherat M. Diacerein in the treatment of osteoarthritis: A meta-analysis of randomized controlled trials. *Osteoarthritis Cartilage.* 2001;9(4):327-36.
 21. Roth SH. Diclofenac in the treatment of osteoarthritis: A comprehensive review. *Open Access J.* 2025;15(3):45-52.
 22. Chen ZR, Chen BK, Li P, Feng K. Efficacy and safety of different topical diclofenac formulations for knee osteoarthritis: A meta-analysis. *BMC Musculoskelet Disord.* 2025;26:230.
 23. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zevlin D. Diclofenac sodium topical solution 1.5% for the treatment of osteoarthritis of the knee: A randomized controlled trial. *Clin Ther.* 2009;31(3):595-607.
 24. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: A randomized, double-blind, vehicle-controlled clinical trial. *Arch Intern Med.* 2004;164(18):2017-23.
 25. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. *Cochrane Database Syst Rev.* 2006;(1):CD004257.
 26. Schnitzer TJ, Kivitz AJ, Frayssinet H, Duquesroix B. Efficacy and safety of topical diclofenac patch for knee osteoarthritis: A randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage.* 2010;18(3):289-96.
 27. Barthel HR, Haselwood DM, Longley S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. *Semin Arthritis Rheum.* 2009;39(3):203-12.
 28. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. *CMAJ.* 2004;171(4):333-8.
 29. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. *Lancet.* 2005;365(9463):965-73.
 30. Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum.* 2014;44(3):253-63.
 31. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet.* 2019;393(10182):1745-59.
 32. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Arden NK, Hochberg MC, et al. Selective COX-2 inhibitors for osteoarthritis: A systematic review and meta-analysis of safety and efficacy within

- randomized controlled trials. *Osteoarthritis Cartilage.* 2013;21(8):1041-51.
33. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: An evidence-based approach to the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann Rheum Dis.* 2003;62(12):1145-55.
 34. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage.* 2014;22(3):363-88.
 35. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum.* 2000;43(9):1905-15.
 36. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev.* 2006;(2):CD005321.
 37. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. *Lancet.* 2005;365(9463):965-73.